Details of the Drug

General Information of Drug (ID: DMVXBSW)

Drug Name

BTZ-043

Synonyms

BTZ043; 1161233-85-7; BTZ-043; BTZ-10526043; UNII-G55ZH52P57; 2-[(3S)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one; Bzt043; MMV676603; SCHEMBL2488829; (S)-2-(2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one; 4H-1,3-Benzothiazin-4-one, 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-; G55ZH52P57; 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one; BTZ 043; GTUIRORNXIOHQR-VIFPVBQESA-N; 4H-1,3-BENZOTHIAZIN-4-ONE, 2-((2S)-2-METHYL-1,4-DIOXA-8-AZASPIRO(4.5)DEC-8-YL)-8-NITRO-6-(TRIFLUOROMETHYL)-; BTZ043-racemate; S1097_Selleck; PBTZ 169; CHEMBL1822872; GTPL13034; DTXSID80151286; BCPP000312; EX-A1012; MFCD17215196; AKOS030526000; BCP9000457; CS-5635; AC-35368; AS-74893; BTZ 10526043; HY-13579; EN300-23853592; Q27278777; [2-[(3S)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-4-oxo-6-(trifluoromethyl)-1,3-benzothiazin-8-yl]azinic acid; 2-((2S)-2-METHYL-1,4-DIOXA-8-AZASPIRO(4.5)DECAN-8-YL)-8-NITRO-6-TRIFLUOROMETHYL-4H-1,3-BENZOTHIAZIN-4-ONE

Indication

Disease Entry	ICD 11	Status	REF
Tuberculosis	1B10-1B14	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C17H16F3N3O5S
Canonical SMILES: CC1COC2(O1)CCN(CC2)C3=NC(=O)C4=C(S3)C(=CC(=C4)C(F)(F)F)[N+](=O)[O-]
InChI: InChI=1S/C17H16F3N3O5S/c1-9-8-27-16(28-9)2-4-22(5-3-16)15-21-14(24)11-6-10(17(18,19)20)7-12(23(25)26)13(11)29-15/h6-7,9H,2-5,8H2,1H3/t9-/m0/s1
InChIKey: GTUIRORNXIOHQR-VIFPVBQESA-N

Cross-matching ID

PubChem CID: 42609849
TTD ID: DVK21S

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)	TTLOHU4	DPRE1_MYCTU	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04044001) A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of TB